StartUPDATES: New developments for healthcare startups
Check out news from Opala, Equiva, Sling Therapeutics, Quil, and Third Rock Ventures.
Biotech startup Septerna lands $100M to break new ground on an old drug target
Septerna has science from a Nobel laureate and technology that finds new ways to drug GPCRs, well-validated receptors targeted by about one-third of FDA-approved medicines. According to CEO Jeff Finer, the startup is kicking off a second golden age of GPCR drug development.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Third Rock-backed Abata gets $95M to take cell therapy to MS, other autoimmune diseases
Regulatory T cells, or Tregs, have shown promise as a treatment for autoimmune diseases. Abata Therapeutics has raised $95 million in Series A financing for its Treg technology and CEO Samantha Singer said that multiple sclerosis is the startup's first disease target.
Liquid biopsy firm Thrive launches with $110M Series A round
The company has a 10,000-patient prospective trial with Geisinger fully enrolled to test CancerSEEK, a test developed at Johns Hopkins University.
Maze Therapeutics launches with nearly $200M to explore genetic modifiers’ role in disease
Third Rock and ARCH led the launch of the company, which will look at ways to target genetic modifiers that can protect against certain diseases.
Life sciences VC investment trends similar to tech, but there are differences
Deals worth $50 million or more are becoming more frequent, even in Series A. But a VC investor said underlying drivers in life sciences are different from the technology sector.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Ambys Medicines garners $140 million to develop chronic liver disease treatments
The company secured $60 million in a Series A round from Third Rock and Takeda, plus a partnership with Takeda.
Third Rock invests $55M in ‘kidney renaissance’ startup
Third Rock Ventures has incubated, funded and launched another startup, Goldfinch Bio, committing $55M to its mission to modernize the treatment of kidney disease.
Third Rock Ventures closes $616 million healthcare fund
Boston-based Third Rock Ventures announced Monday that it had closed its largest fund to date, raising $616 million for new investments in neurology, immunology, genetic disorders and more.
Protein-motion startup launches armed with $57M to develop drugs, crack cancer code
Relay Therapeutics is aiming to identify the way proteins in cells move and shift and morph, and this understanding can help open the door to new, more effective drugs.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
NinePoint Medical adds roughly $31M to back its imaging technology
Massachusetts-based NinePoint Medical has raised about $30.7 million to go toward its medical imaging technology that allows visibility to large areas of tissue in order to more precisely detect areas that would need to be biopsied.
Third Rock hearing loss startup Decibel Therapeutics launches with $52M
Decibel Therapeutics, a Third Rock-backed startup, was just launched in Boston to treat a wide range of hearing loss disorders. It just closed out a $52 million Series A.
MIT develops implantable micro-device that gauges efficacy of cancer drugs; Third Rock partner involved
With precision medicine in its infancy, it’s still difficult to determine which chemotherapy drugs are appropriate for a patient. MIT researchers have developed a device the size of a grain of rice that can be implanted into a patient, and carry small doses of up to 30 different drugs that can be delivered in tandem. When implanted in […]
Like a Lego: Third Rock’s $45M venture makes synthesizing nature’s drugs modular
Nature’s been a fantastically bountiful source of medicine, sure. But turns out the drug compounds found secreted by a sea sponge or on the underside of a log have very elaborate chemical structures. When used for unintended purposes like, say, treating humans, these compounds can both help and harm. Third Rock Ventures just funneled an impressive $45 million to launch […]
With IP from Mass Gen & funding from Third Rock, NinePoint carves niche in in-vivo imaging
When NinePoint Medical Inc. got its first seed funding from Third Rock Ventures and Prospect Venture Partners back in 2009, it didn’t have a prototype or a design, or even a product. What it did have was an idea — to create a medical device that would bring together access, diagnosis and treatment — and […]